Expert opinion on pharmacotherapy
-
Expert Opin Pharmacother · Jan 2013
Review Meta AnalysisSecond-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
A systematic review/meta-analysis was conducted to assess the effectiveness and safety of second-line treatments for advanced renal cell carcinoma (RCC), which includes the vascular endothelial growth factor inhibitor axitinib. ⋯ Results from the present study suggest that axitinib will be an important treatment option to extend PFS in the management of advanced RCC in the second-line setting. Ongoing research will define the optimal treatment algorithm leading to a patient-focused treatment strategy.